CN110051650A - The nanoparticle pharmaceutical that bevacizumab and dexamethasone for intravitreal injection carry altogether - Google Patents
The nanoparticle pharmaceutical that bevacizumab and dexamethasone for intravitreal injection carry altogether Download PDFInfo
- Publication number
- CN110051650A CN110051650A CN201910353060.4A CN201910353060A CN110051650A CN 110051650 A CN110051650 A CN 110051650A CN 201910353060 A CN201910353060 A CN 201910353060A CN 110051650 A CN110051650 A CN 110051650A
- Authority
- CN
- China
- Prior art keywords
- dexamethasone
- bevacizumab
- nanoparticle
- plga
- intravitreal injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
- A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses the nanoparticle pharmaceutical that a kind of bevacizumab for intravitreal injection and dexamethasone carry altogether, by the way that dexamethasone and bevacizumab are combined using PLGA as the nanoparticle of matrix, it is prepared for the nanoparticle (Bev/Dex-PLGA NPs) that bevacizumab and dexamethasone carry altogether, forms the Nano medication delivery system with core-shell structure.It solves the deficiency of dexamethasone half-life short, ensure that the high activity of bevacizumab in preparation process, anti-angiogenesis effect is effectively improved by the two synergistic effect.The Nano medication delivery system that the bevacizumab and dexamethasone that the present invention constructs carry altogether is a kind of excellent delivery system, is expected to the treatment applied to age-related macular degeneration (AMD).
Description
Technical field
The present invention discloses the nanoparticle pharmaceutical delivering that a kind of bevacizumab for intravitreal injection and dexamethasone carry altogether
System, while the preparation method of the nanoparticle pharmaceutical delivery system is additionally provided, it is related to pharmaceutical technology field.
Background technique
Glucocorticoid medicine is clinical ophthalmology common drug, intraocular to retina choroid new vessels etc. Hypertrophic
The entophthamia such as lesion and uveitis, retinal vasculitis have definite curative effect.In view of its systemic toxic side effect and eye
The distinctive barrier structure of ball, it is considered that intravitreal approach is administered better than oral or intravenous.But word in vitreum
Drug metabolism is eliminated very fast after administration, and drug effect is of short duration；Multiple dosing then will increase intraocular hemorrhage, cataract, detachment of retina etc.
The incidence of complication.Poly lactic-co-glycolic acid (PLGA) nanoparticle is have biological degradability and biocompatibility novel
Atrigel, it is expected to which part reaches long-acting, stable drug concentration within the eye.
Dexamethasone is glucocorticoid medicine, has anti-inflammatory, antiendotoxin, immune, Hemorrhagic shock and enhancing is inhibited to answer
Swash the pharmacological actions such as reaction, therefore is widely used in each section and treats a variety of diseases, such as autoimmune disease, allergy, inflammation, asthma
And dermatology and ophthalmology disease.Studies have shown that glucocorticoid can by release local noradrenaline vasoconstriction,
Reduction or the expression of silencing vascular endothelial growth factor (VEGF), induction of vascular endothelial Apoptosis inhibit blood vessel endothelium proliferation.
Glucocorticoid has quick, powerful and nonspecific anti-inflammatory effect simultaneously.It is effective to various inflammation.
Bevacizumab (Avastin®) be recombination Humanized monoclonal antibodies, it comprises the structural area of human antibody and
In combination with the complementary determining region of the source of mouse monoclonal antibody of VEGF, it can be combined with human vascular endothelial growth factor (VEGF) and block its biology
Activity.It is the medicine of the inhibition Tumor Angiongesis of first, the U.S. listing that gets the Green Light.The U.S. has doctor clinical successively in recent years
It is found when treatment, since Avastin effective object is anti-Vascular Endothelial outgrowth factor (VEGF), it is abnormal macula area can be neutralized
High concentration eye illness VEGF, thus inhibit age-related macular degeneration (AMD) deteriorate, it is common for treating this elderly
, the eye disease successful that can lead to severe visual damage is very big.Avastin®Because confirming that there is treatment retinopathy by clinical practice
Effect and cheap, is widely applied by oculist always.
Treated with combined medication is concerned because that may generate the therapeutic effect for being substantially better than drug single therapy.Rationally
Drug combination can play the synergistic effect of drug effectively to improve curative effect, can also be dropped by reducing single pharmaceutical quantities
Low adverse reaction.
Summary of the invention
The present invention discloses the Nano medication that a kind of bevacizumab for intravitreal injection and dexamethasone carry altogether, solves
The deficiency of dexamethasone half-life short ensure that the high activity of bevacizumab in preparation process.
The present invention provides the nanoparticle pharmaceuticals that a kind of bevacizumab for intravitreal injection and dexamethasone carry altogether, are
Surface for intravitreal injection connects bevacizumab, and inside loads the nanoparticle pharmaceutical delivery system of dexamethasone.Nanoparticle
PLGA in matrix enables to dexamethasone slowly steadily to discharge；Bevacizumab is connected to by covalent bond using PLGA as matrix
Nanoparticle surface, still ensure that bevacizumab and VEGF effect activity；Two kinds of drug synergisms, drug combination are significant
Improve anti-angiogenesis effect.
Invention further provides the nanometer medicines that a kind of bevacizumab for intravitreal injection and dexamethasone carry altogether
The preparation method of object.
The Nano medication that a kind of bevacizumab and dexamethasone for intravitreal injection of the present invention carries altogether, passes through
Following technical scheme is realized:
By the ground plug in the polymer nanoparticle of the core-shell structure prepared using high molecular polymer PLGA as carrier material, nanoparticle
Meter Song and the bevacizumab of nanoparticle surface connection are constituted.
The system for the Nano medication that a kind of bevacizumab and dexamethasone for intravitreal injection of the present invention carries altogether
Preparation Method, comprising the following steps:
1) the PLGA nanoparticle of dexamethasone is contained using emulsion-solvent evaporation method preparation；
2) method for using chemical coupling, sends out the amino of the carboxyl and bevacizumab in the PLGA of nanoparticle using activator
Raw covalent reaction, antibody is connect with nanoparticle.
The system for the Nano medication that a kind of bevacizumab and dexamethasone for intravitreal injection of the present invention carries altogether
Preparation Method, it is characterised in that specifically includes the following steps:
1) 5~20mg dexamethasone is weighed respectively, and 20mg PLGA is dissolved in acetone, ultrasonic dissolution, as organic phase；
2) polyvinyl alcohol (PVA) aqueous solution for taking 5~20mL 0.5% ~ 5%, as water phase；
3) organic phase is added dropwise in water phase under the conditions of magnetic agitation, room temperature continues to stir at low speed, and volatilization eliminates dichloro
Methane eccentric cleaning 3 times, is collected dexamethasone-PLGA nanoparticle and is lyophilized；
4) take the above-mentioned nanometer of 10mg in 10ml 1mol/L hydrochloric acid, and be added 5mg n-hydroxysuccinimide (NHS) and
20mg 1- (3- dimethylamino-propyl) -3- ethyl-carbodiimide hydrochloride (EDC) is centrifuged off after activating nanoparticle 4h
Clearly；
5) nanoparticle and 5~20mg bevacizumab activated is incubated in jointly in pH7.4 PBS, and connection 3~for 24 hours, eccentric cleaning 3
Salt ion in the secondary bevacizumab and buffer not connected with removing, collects and is lyophilized and cut down to get the shellfish for intravitreal injection
The Nano medication delivery system that monoclonal antibody and dexamethasone carry altogether.
PLGA of the present invention is carboxy blocking, model 7525 1.5A or 5050 2A.
Dexamethasone of the present invention and PLGA mass ratio are (1~4): 4.
Bevacizumab of the present invention and dexamethasone-PLGA nanoparticle mass ratio are 2: (1~4).
The nanoparticle (Bev/Dex-PLGA NPs) that bevacizumab and dexamethasone of the present invention carry altogether is freeze-drying system
Agent, belongs to intravitreal system, and solvent is usually sterile isotonic aqueous solution.
The positive effect of the present invention is:
By combining dexamethasone and bevacizumab using PLGA as the nanoparticle of matrix, it is prepared for bevacizumab and dexamethasone
The nanoparticle (Bev/Dex-PLGA NPs) carried altogether, forms the Nano medication delivery system with core-shell structure.It solves
The deficiency of dexamethasone half-life short ensure that the high activity of bevacizumab in preparation process, be acted synergistically by the two effective
Improve anti-angiogenesis effect.The Nano medication delivery system that the bevacizumab and dexamethasone that the present invention constructs carry altogether, is one
The excellent delivery system of kind, is expected to the treatment applied to age-related macular degeneration (AMD).
Detailed description of the invention:
Fig. 1 is the grain size distribution of nanoparticle；
Fig. 2 is the potential image of nanoparticle；
Fig. 3 is that the SEM of nanoparticle schemes；
Fig. 4 is the tablets in vitro curve of nanoparticle；
Fig. 5 is the experiment of bevacizumab high performance liquid chromatography；
Fig. 6 is the experiment of bevacizumab circular dichroism spectra；
Fig. 7 is bevacizumab fluorescence spectrum experiments；
Fig. 8 is the cytotoxicity experiment of nanoparticle；
Fig. 9 is that the internal anti-angiogenesis of nanoparticle is tested.
Specific embodiment
Specific implementation method of the invention, by following embodiment for example, but protection scope of the present invention do not limit to
In this.
Embodiment 1
1) 5mg dexamethasone is weighed respectively, and 7525 1.5A of 20mg PLGA is dissolved in acetone, ultrasonic dissolution, as organic
Phase；
2) polyvinyl alcohol (PVA) aqueous solution for taking 5mL 0.5%, as water phase；
3) organic phase is added dropwise in water phase under the conditions of magnetic agitation, room temperature continues to stir at low speed, and volatilization eliminates dichloro
Methane eccentric cleaning 3 times, is collected dexamethasone-PLGA nanoparticle and is lyophilized；
4) take the above-mentioned nanometer of 10mg in 10ml 1mol/L hydrochloric acid, and be added 5mg n-hydroxysuccinimide (NHS) and
20mg 1- (3- dimethylamino-propyl) -3- ethyl-carbodiimide hydrochloride (EDC) is centrifuged off after activating nanoparticle 4h
Clearly；
5) nanoparticle and 5mg bevacizumab activated is incubated in jointly in pH7.4 PBS, connects 12h, eccentric cleaning 3 times to remove
Remove salt ion in not connected bevacizumab and buffer, collect and be lyophilized to get for intravitreal injection bevacizumab and
The Nano medication delivery system that dexamethasone carries altogether.
Embodiment 2
1) 10mg dexamethasone is weighed respectively, and 7525 1.5A of 20mg PLGA is dissolved in acetone, ultrasonic dissolution, as organic
Phase；
2) polyvinyl alcohol (PVA) aqueous solution for taking 5mL 0.5%, as water phase；
3) organic phase is added dropwise in water phase under the conditions of magnetic agitation, room temperature continues to stir at low speed, and volatilization eliminates dichloro
Methane eccentric cleaning 3 times, is collected dexamethasone-PLGA nanoparticle and is lyophilized；
4) take the above-mentioned nanometer of 10mg in 10ml 1mol/L hydrochloric acid, and be added 5mg n-hydroxysuccinimide (NHS) and
20mg 1- (3- dimethylamino-propyl) -3- ethyl-carbodiimide hydrochloride (EDC) is centrifuged off after activating nanoparticle 4h
Clearly；
5) nanoparticle and 5mg bevacizumab activated is incubated in jointly in pH7.4 PBS, connects 12h, eccentric cleaning 3 times to remove
Remove salt ion in not connected bevacizumab and buffer, collect and be lyophilized to get for intravitreal injection bevacizumab and
The Nano medication delivery system that dexamethasone carries altogether.
Embodiment 3
1) 10mg dexamethasone is weighed respectively, and 7525 1.5A of 20mg PLGA is dissolved in acetone, ultrasonic dissolution, as organic
Phase；
2) polyvinyl alcohol (PVA) aqueous solution for taking 5mL 2%, as water phase；
3) organic phase is added dropwise in water phase under the conditions of magnetic agitation, room temperature continues to stir at low speed, and volatilization eliminates dichloro
Methane eccentric cleaning 3 times, is collected dexamethasone-PLGA nanoparticle and is lyophilized；
4) take the above-mentioned nanometer of 10mg in 10ml 1mol/L hydrochloric acid, and be added 5mg n-hydroxysuccinimide (NHS) and
20mg 1- (3- dimethylamino-propyl) -3- ethyl-carbodiimide hydrochloride (EDC) is centrifuged off after activating nanoparticle 4h
Clearly；
5) nanoparticle and 5mg bevacizumab activated is incubated in jointly in pH7.4 PBS, connects 12h, eccentric cleaning 3 times to remove
Remove salt ion in not connected bevacizumab and buffer, collect and be lyophilized to get for intravitreal injection bevacizumab and
The Nano medication delivery system that dexamethasone carries altogether.
Embodiment 4
1) 10mg dexamethasone is weighed respectively, and 7525 1.5A of 20mg PLGA is dissolved in acetone, ultrasonic dissolution, as organic
Phase；
2) polyvinyl alcohol (PVA) aqueous solution for taking 10mL 2%, as water phase；
3) organic phase is added dropwise in water phase under the conditions of magnetic agitation, room temperature continues to stir at low speed, and volatilization eliminates dichloro
Methane eccentric cleaning 3 times, is collected dexamethasone-PLGA nanoparticle and is lyophilized；
4) take the above-mentioned nanometer of 10mg in 10ml 1mol/L hydrochloric acid, and be added 5mg n-hydroxysuccinimide (NHS) and
20mg 1- (3- dimethylamino-propyl) -3- ethyl-carbodiimide hydrochloride (EDC) is centrifuged off after activating nanoparticle 4h
Clearly；
5) nanoparticle and 5mg bevacizumab activated is incubated in jointly in pH7.4 PBS, connects 12h, eccentric cleaning 3 times to remove
Remove salt ion in not connected bevacizumab and buffer, collect and be lyophilized to get for intravitreal injection bevacizumab and
The Nano medication delivery system that dexamethasone carries altogether.
Embodiment 5
1) 10mg dexamethasone is weighed respectively, and 5050 2A of 20mg PLGA is dissolved in acetone, ultrasonic dissolution, as organic phase；
2) polyvinyl alcohol (PVA) aqueous solution for taking 5mL 2%, as water phase；
3) organic phase is added dropwise in water phase under the conditions of magnetic agitation, room temperature continues to stir at low speed, and volatilization eliminates dichloro
Methane eccentric cleaning 3 times, is collected dexamethasone-PLGA nanoparticle and is lyophilized；
4) take the above-mentioned nanometer of 10mg in 10ml 1mol/L hydrochloric acid, and be added 5mg n-hydroxysuccinimide (NHS) and
20mg 1- (3- dimethylamino-propyl) -3- ethyl-carbodiimide hydrochloride (EDC) is centrifuged off after activating nanoparticle 4h
Clearly；
5) nanoparticle and 5mg bevacizumab activated is incubated in jointly in pH7.4 PBS, connects 12h, eccentric cleaning 3 times to remove
Remove salt ion in not connected bevacizumab and buffer, collect and be lyophilized to get for intravitreal injection bevacizumab and
The Nano medication delivery system that dexamethasone carries altogether.
Embodiment 6
1) 10mg dexamethasone is weighed respectively, and 7525 1.5A of 20mg PLGA is dissolved in acetone, ultrasonic dissolution, as organic
Phase；
2) polyvinyl alcohol (PVA) aqueous solution for taking 5mL 2%, as water phase；
3) organic phase is added dropwise in water phase under the conditions of magnetic agitation, room temperature continues to stir at low speed, and volatilization eliminates dichloro
Methane eccentric cleaning 3 times, is collected dexamethasone-PLGA nanoparticle and is lyophilized；
4) take the above-mentioned nanometer of 10mg in 10ml 1mol/L hydrochloric acid, and be added 5mg n-hydroxysuccinimide (NHS) and
20mg 1- (3- dimethylamino-propyl) -3- ethyl-carbodiimide hydrochloride (EDC) is centrifuged off after activating nanoparticle 4h
Clearly；
5) nanoparticle and 10mg bevacizumab activated is incubated in jointly in pH7.4 PBS, connects 12h, eccentric cleaning 3 times to remove
Remove salt ion in not connected bevacizumab and buffer, collect and be lyophilized to get for intravitreal injection bevacizumab and
The Nano medication delivery system that dexamethasone carries altogether.
Embodiment 7
1) 10mg dexamethasone is weighed respectively, and 7525 1.5A of 20mg PLGA is dissolved in acetone, ultrasonic dissolution, as organic
Phase；
2) polyvinyl alcohol (PVA) aqueous solution for taking 5mL 2%, as water phase；
3) organic phase is added dropwise in water phase under the conditions of magnetic agitation, room temperature continues to stir at low speed, and volatilization eliminates dichloro
Methane eccentric cleaning 3 times, is collected dexamethasone-PLGA nanoparticle and is lyophilized；
4) take the above-mentioned nanometer of 10mg in 10ml 1mol/L hydrochloric acid, and be added 5mg n-hydroxysuccinimide (NHS) and
20mg 1- (3- dimethylamino-propyl) -3- ethyl-carbodiimide hydrochloride (EDC) is centrifuged off after activating nanoparticle 4h
Clearly；
5) nanoparticle and 10mg bevacizumab activated is incubated in jointly in pH7.4 PBS, connects 6h, eccentric cleaning 3 times to remove
Remove salt ion in not connected bevacizumab and buffer, collect and be lyophilized to get for intravitreal injection bevacizumab and
The Nano medication delivery system that dexamethasone carries altogether.
Embodiment 8
1) 10mg dexamethasone is weighed respectively, and 7525 1.5A of 20mg PLGA is dissolved in acetone, ultrasonic dissolution, as organic
Phase；
2) polyvinyl alcohol (PVA) aqueous solution for taking 5mL 2%, as water phase；
3) organic phase is added dropwise in water phase under the conditions of magnetic agitation, room temperature continues to stir at low speed, and volatilization eliminates dichloro
Methane eccentric cleaning 3 times, is collected dexamethasone-PLGA nanoparticle and is lyophilized；
4) take the above-mentioned nanometer of 10mg in 10ml 1mol/L hydrochloric acid, and be added 5mg n-hydroxysuccinimide (NHS) and
20mg 1- (3- dimethylamino-propyl) -3- ethyl-carbodiimide hydrochloride (EDC) is centrifuged off after activating nanoparticle 4h
Clearly；
5) nanoparticle and 10mg bevacizumab activated is incubated in jointly in pH7.4 PBS, connects 18h, eccentric cleaning 3 times to remove
Remove salt ion in not connected bevacizumab and buffer, collect and be lyophilized to get for intravitreal injection bevacizumab and
The Nano medication delivery system that dexamethasone carries altogether.
Effect experimental examples 1 (characterization of nanoparticle: partial size, current potential, form)
Experimental material:
Bev/Dex-PLGA NPs, silicon wafer, deionized water of embodiment 1 etc..
Experimental procedure:
With the Bev/Dex-PLGA NPs concentration of deionized water dilution embodiment 1 to 1 mg/mL, it is analyzed using laser particle analyzer
Partial size and Potential distribution.
With the Bev/Dex-PLGA NPs concentration of deionized water dilution embodiment 1 to 1 mg/mL, it is added dropwise one and drops to silicon wafer load
Water is eliminated in room temperature volatilization after on body.After sample metal spraying processing on silicon wafer, scanning electron microscope is used under 3 kV voltages
(SEM) nanoparticle configuration of surface is observed
Experimental result:
Using the partial size and Potential distribution of the Bev/Dex-PLGA NPs of laser particle analyzer analysis embodiment 1, particle diameter distribution is such as
Shown in Fig. 1, Potential distribution is as shown in Figure 2.Droplet measurement the results show that the average grain diameter of Bev/Dex-PLGA NPs in 150-
Between 200nm, current potential is in 0mV or so.
Using the configuration of surface of the Bev/Dex-PLGA NPs in scanning electron microscope (SEM) observation embodiment 6, such as scheme
Shown in 3.SEM is the results show that Bev/Dex-PLGA NPs is rounded, and surface is smooth, and size is between 150-200nm.
Effect experimental examples 2 (drugloading rate of nanoparticle and release in vitro behavior are investigated)
Experimental material:
Bev/Dex-PLGA NPs, dexamethasone, acetonitrile, 0.22 μm of miillpore filter, BCA kit in Examples 1 to 8 etc..
Experimental procedure:
Using the encapsulating of dexamethasone in the Bev/Dex-PLGA NPs in high performance liquid chromatography (HPLC) measurement Examples 1 to 8
Rate:
1) 10mg freeze-drying Bev/Dex-PLGA NPs is weighed, is dissolved in 1mL acetonitrile, spiral dissolves 10 min, is added 9mL's
40% acetonitrile solution, 0.22 μm of filtering with microporous membrane, filtered fluid carry out chromatography.
2) HPLC condition: mobile phase acetonitrile: water (40:60, v/v) solution, flow velocity 1mL/min, Detection wavelength 240nm, into
20 μ L of sample amount.
3) calculate according to the following formula quality/investment nanoparticle gross mass of drugloading rate (DL%)=measure dexamethasone ×
100%, quality/investment dexamethasone quality × 100% of encapsulation rate (EE%)=measure dexamethasone.
Using the connection of bevacizumab in the Bev/Dex-PLGA NPs in BCA kit method measurement Examples 1 to 8
Rate:
1) supernatant in nanoparticle antibody connection procedure is collected, the free shellfish in supernatant is detected by BCA kit and is cut down
Monoclonal antibody.
2) the free bevacizumab of calculating antibody bonding ratio (CB%)=investment bevacizumab gross mass-according to the following formula
Quality/Bev/Dex-PLGA nanoparticle gross mass.Measuring bonding ratio is 20~40%(table 1)
Using the release in vitro behavior of the Bev/Dex-PLGA NPs in the method analysis embodiment 6 of dialysis:
1) vitro Release Medium: 7.4 PBS(1% Tween-80 of pH), dialysis bag retention molecular weight (MWCO, 8kD).
2) sample point: 0.5h, 1h, 2h, 4h, 6h, 8h, 12h, 1d, 2d, 3d.HPLC detects dexamethasone content, and calculates
The preparation of dexamethasone.
Experimental result:
Using the encapsulating of dexamethasone in the Bev/Dex-PLGA NPs in high performance liquid chromatography (HPLC) measurement Examples 1 to 8
Rate, measuring encapsulation rate is 50% ~ 75%(table 1).
Using the connection of bevacizumab in the Bev/Dex-PLGA NPs in BCA kit method measurement Examples 1 to 8
Rate, measuring bonding ratio is 20~40%(table 1)
Using the release in vitro behavior of the Bev/Dex-PLGA NPs in the method analysis embodiment 6 of dialysis, as a result as shown in Figure 4
There is slow release behavior after burst release in Bev/Dex-PLGA NPs, adds up release rate in 72 h up to 81.3%.Release behavior table
It is now sustained again to be first released, and slow release effect is obvious.This is attributed to the fact that the presence of the core-shell structure and surface antibody of nanoparticle,
After the degradation characteristic of PLGA has delayed the release of dexamethasone, surface to be coupled monoclonal antibody, releasing for dexamethasone is further delayed
It puts, maintains the treatment concentration of dexamethasone within a certain period of time.
Nanoparticle dexamethasone drugloading rate, encapsulation rate and bevacizumab bonding ratio obtained by 1 Examples 1 to 8 of table
| DL(%) | EE(%) | CB(%) | |
| Embodiment 1 | 10.64±0.56 | 53.24±0.77 | 22.47±0.13 |
| Embodiment 2 | 19.08±0.06 | 57.83±0.46 | 25.72±0.09 |
| Embodiment 3 | 22.07±0.47 | 66.88±0.03 | 36.67±0.08 |
| Embodiment 4 | 20.89±0.54 | 63.32±0.67 | 29.87±0.04 |
| Embodiment 5 | 18.56±0.61 | 56.23±0.08 | 24.32±0.37 |
| Embodiment 6 | 23.21±0.35 | 70.33±0.09 | 32.74±0.08 |
| Embodiment 7 | 23.61±0.42 | 71.56±0.78 | 33.33±0.52 |
| Embodiment 8 | 24.71±0.66 | 74.87±0.33 | 37.64±0.12 |
* DL is dexamethasone drugloading rate；EE is dexamethasone encapsulation rate；CB is bevacizumab bonding ratio.
Effect experimental examples 3 (bevacizumab stability study)
Experimental material:
Apply free bevacizumab, acetonitrile, the BCA kit, phosphorus in the nanoparticle Incubating Solution of the Bev/Dex-PLGA NPs in example 6
Acid dihydride sodium, disodium hydrogen phosphate etc..
Experimental procedure:
To investigate influence of the Bev/Dex-PLGA NPs preparation process to bevacizumab stability, we take the Bev/ applied in example 6
Free bevacizumab in the nanoparticle Incubating Solution of Dex-PLGA NPs is investigated by HPLC, circular dichroism spectra, fluorescence spectrum respectively
Its level-one, second level, the stability of tertiary structure.
With the stability of HPLC detection bevacizumab primary structure, Herceptin solution is diluted or is concentrated before detection
To 0.5mg/mL, HPLC condition: mobile phase acetonitrile: water (40:60, v/v) solution, flow velocity 1mL/min, Detection wavelength 240nm, into
20 μ L of sample amount.
Using the stability of circular dichroism spectrometer detection bevacizumab secondary structure, Herceptin solution is diluted before detection
Or it is concentrated to 10-5 Mol/L, circular dichroism spectra scanning wavelength 190 ~ 260nm of range detect 25 DEG C of temperature.Using Jasco software
Background correction solution signal, is converted to mean residue ellipticity for result.
Using the stability of Fluorescence Spectrometer detection bevacizumab tertiary structure, Herceptin solution is diluted before detection
Or it is concentrated to 1mol/L, fluorescence spectrum excitation wavelength 280nm, 305 ~ 550nm of launch wavelength.Background correction solution letter before testing
Number, record fluorescence spectra.
Experimental result:
The stability result of bevacizumab primary structure such as Fig. 5 in nanoparticle Incubating Solution, with natural antibody appearance time almost one
It causes, illustrates that the antibody in Incubating Solution remains complete antibody structure, there is no denaturation to assemble.
Secondary structure is the basis for guaranteeing its bioactivity, and the change of secondary structure may influence protein
Activity.The bevacizumab secondary structure variation such as bevacizumab in Fig. 6, PBS(pH 7.4) presents apparent negative at 212nm
Peak, and the antibody negative peak in Incubating Solution is still obvious, illustrates that secondary structure does not almost change.
The activity of protein keeps relying on its distinctive tertiary structure, and when the tertiary structure of protein changes, activity must
It will be destroyed.There is fluorescence at 330nm in the bevacizumab tertiary structure variation such as bevacizumab in Fig. 7, PBS(pH 7.4)
Spectrum peak, and the antibody fluorescence spectrum peak in Incubating Solution and PBS coincide substantially, illustrate that tertiary structure does not almost change.
Above results proved that Bev/Dex-PLGA NPs of the invention ensure that the high activity of wherein bevacizumab.
Effect experimental examples 4 (cytotoxicity experiment)
Experimental material:
Human RPE Cells in Vitro (ARPE-19 cell), DMEM/F12 culture medium, fetal calf serum, Pen .- Strep,
96 microwell plates, dexamethasone, bevacizumab, Bev/Dex-PLGA NPs of embodiment 6, MTT, DMSO etc..
Experimental procedure:
In DMEM/F12 culture medium (10% fetal calf serum, 1% Pen .- Strep), culture bottle is set for ARPE-19 cell culture
In 37 DEG C, 5% CO2 incubator.The cell of logarithmic growth phase is tested.With 1 × 104The density in a/hole will in pair
The cell inoculation of number phase is in 96 microwell plates, and 37 DEG C of cultures make its adherent for 24 hours, and second day removal culture solution is separately added into and contains
After 37 DEG C are incubated for for 24 hours, MTT examination is added in medicine (dexamethasone, bevacizumab, the Bev/Dex-PLGA NPs of embodiment 6) culture medium
Agent detects and calculates cell survival rate.
Experimental result:
As a result as shown in figure 8, dexamethasone, bevacizumab, Bev/Dex-PLGA NPs show as almost without toxicity, it was demonstrated that
Its ophthalmic administration safe and feasible, it is free of toxic effects to ocular cell ARPE-19.
Effect experimental examples 5 (anti-angiogenesis experiment)
Experimental material:
Fertilized eggs, methylcellulose, dexamethasone, bevacizumab, Bev/Dex-PLGA NPs of embodiment 6, physiological saline
Deng.
Experimental procedure:
Influence using chick chorioallantoic membrane (CAM) experimental evaluation Bev/Dex-PLGA NPs to anti-angiogenesis.In embryonic development
The 4th day, the gas chamber of each egg opens one small window (diameter: ~ 10mm).It is with about 2 millimeters of carboxymethyl cellulose films of diameter
Pharmaceutical carrier.At embryonic period, embryonic phase the 6th day, drug containing dexamethasone, bevacizumab, the Bev/Dex-PLGA NPs of embodiment 6) carrier is light
Gently it is implanted into each CAM.It is incubated for the 8th day, 3.7% formaldehyde is fixed and taken pictures.Calculate the blood vessel number in each CAM.For blood vessel amount
Change, negative control group (physiological saline) value is set as 100%.
Experimental result:
CAM experimental result Avastin as shown in Figure 9 and dexamethasone can inhibit the growth of new blood vessel, to promote
The significant decrease of vessel density.The blood vessel number of bevacizumab group and Dexamethasone group is reduced to 65.2% and 83.4%, and Bev/
Dex-PLGA NPs group is reduced to 42.7%.These statistics indicate that, Bev/Dex-PLGA NPs anti-angiogenic rebirth effect of the invention
Most preferably, two kinds of drug synergisms, drug combination significantly improve anti-angiogenesis effect.
Conclusion:
The Nano medication delivery system Bev/ that a kind of bevacizumab and dexamethasone for intravitreal injection of the invention carries altogether
The surface Dex-PLGA NPs is in smooth spheroidal, and average grain diameter is between 150-200nm, and current potential is in 0mV or so.Stall off a meter bale breaking
Envelope rate is in 50% to 75% range, and bevacizumab bonding ratio is in 20% to 40% range.Release behavior shows as first being released to be delayed again
It releases, and slow release effect is obvious.This is attributed to the fact that the presence of the core-shell structure and surface antibody of nanoparticle, and the degradation characteristic of PLGA prolongs
Delay the release of dexamethasone further to have delayed the release of dexamethasone after surface is coupled monoclonal antibody, tieed up within a certain period of time
The treatment concentration of dexamethasone is held.Bev/Dex-PLGA NPs anti-angiogenic rebirth excellent, two kinds of drug synergisms, connection
It shares medicine and significantly improves anti-angiogenesis effect.
Claims (7)
1. a kind of Nano medication that bevacizumab and dexamethasone for intravitreal injection carry altogether, it is characterised in that: You Yigao
Molecularly Imprinted Polymer PLGA is polymer nanoparticle, the dexamethasone and nanometer in nanoparticle of the core-shell structure of carrier material preparation
The bevacizumab of grain surface connection is constituted.
2. a kind of Nano medication that bevacizumab and dexamethasone for intravitreal injection carry altogether as described in claim 1 is passed
Send system, it is characterised in that: PLGA is carboxy blocking, model 7525 1.5A or 5050 2A.
3. a kind of Nano medication that bevacizumab and dexamethasone for intravitreal injection carry altogether as described in claim 1,
It is characterized by: dexamethasone and PLGA mass ratio are (1~4): 4.
4. bevacizumab and dexamethasone-PLGA nanoparticle mass ratio are 2: (1~4).
5. a kind of Nano medication that bevacizumab and dexamethasone for intravitreal injection carry altogether as described in claim 1,
It is characterized by: bevacizumab and dexamethasone-PLGA nanoparticle mass ratio are 2: (1~4).
6. a kind of Nano medication that bevacizumab and dexamethasone for intravitreal injection carry altogether as described in claim 1
Preparation method, comprising the following steps:
1) the PLGA nanoparticle of dexamethasone is contained using emulsion-solvent evaporation method preparation；
2) method for using chemical coupling, sends out the amino of the carboxyl and bevacizumab in the PLGA of nanoparticle using activator
Raw covalent reaction, antibody is connect with nanoparticle.
7. a kind of Nano medication that bevacizumab and dexamethasone for intravitreal injection carry altogether as claimed in claim 5
Preparation method, specifically includes the following steps:
1) 5~20mg dexamethasone is weighed respectively, and 20mg PLGA is dissolved in acetone, ultrasonic dissolution, as organic phase；
2) polyvinyl alcohol (PVA) aqueous solution for taking 5~20mL 0.5% ~ 5%, as water phase；
3) organic phase is added dropwise in water phase under the conditions of magnetic agitation, room temperature continues to stir at low speed, and volatilization eliminates dichloro
Methane eccentric cleaning 3 times, is collected dexamethasone-PLGA nanoparticle and is lyophilized；
4) take the above-mentioned nanometer of 10mg in 10ml 1mol/L hydrochloric acid, and be added 5mg n-hydroxysuccinimide (NHS) and
20mg 1- (3- dimethylamino-propyl) -3- ethyl-carbodiimide hydrochloride (EDC) is centrifuged off after activating nanoparticle 4h
Clearly；
5) nanoparticle and 5~20mg bevacizumab activated is incubated in jointly in pH7.4 PBS, and connection 3~for 24 hours, eccentric cleaning 3
It is secondary to remove salt ion in not connected bevacizumab and buffer, collect and be lyophilized to get.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910353060.4A CN110051650A (en) | 2019-04-29 | 2019-04-29 | The nanoparticle pharmaceutical that bevacizumab and dexamethasone for intravitreal injection carry altogether |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910353060.4A CN110051650A (en) | 2019-04-29 | 2019-04-29 | The nanoparticle pharmaceutical that bevacizumab and dexamethasone for intravitreal injection carry altogether |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110051650A true CN110051650A (en) | 2019-07-26 |
Family
ID=67321390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910353060.4A Pending CN110051650A (en) | 2019-04-29 | 2019-04-29 | The nanoparticle pharmaceutical that bevacizumab and dexamethasone for intravitreal injection carry altogether |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110051650A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114869862A (en) * | 2022-04-24 | 2022-08-09 | 温州医科大学附属眼视光医院 | Glaucoma surgery slow-release anti-scar membrane with drainage function and preparation method thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011053803A2 (en) * | 2009-10-30 | 2011-05-05 | The Ohio State University | Multi-functional biodegradable particles for selectable targeting, imaging, and therapeutic delivery and use thereof for treating ocular disorders |
| CN104159572A (en) * | 2011-09-21 | 2014-11-19 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | Nano delivery systems |
| CN104812397A (en) * | 2012-09-27 | 2015-07-29 | 阿勒根公司 | Biodegradable drug delivery systems for the sustained release of proteins |
| CN104814934A (en) * | 2015-04-28 | 2015-08-05 | 吉林大学 | Herceptin modified paclitaxel-carried targeting nanoparticle transfer system |
| CN105770878A (en) * | 2007-10-12 | 2016-07-20 | 麻省理工学院 | Vaccine Nanotechnology |
| CN103442677B (en) * | 2011-01-24 | 2016-11-09 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | Nano particle for the dermal delivery of medicine and systemic delivery |
| CN106687143A (en) * | 2014-08-01 | 2017-05-17 | 勃林格殷格翰动物保健有限公司 | Nanoparticles, methods of preparation, and uses thereof |
| CN107106509A (en) * | 2014-12-18 | 2017-08-29 | 帝斯曼知识产权资产管理有限公司 | Drug delivery system for delivering acid labile drug |
-
2019
- 2019-04-29 CN CN201910353060.4A patent/CN110051650A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105770878A (en) * | 2007-10-12 | 2016-07-20 | 麻省理工学院 | Vaccine Nanotechnology |
| WO2011053803A2 (en) * | 2009-10-30 | 2011-05-05 | The Ohio State University | Multi-functional biodegradable particles for selectable targeting, imaging, and therapeutic delivery and use thereof for treating ocular disorders |
| CN103442677B (en) * | 2011-01-24 | 2016-11-09 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | Nano particle for the dermal delivery of medicine and systemic delivery |
| CN104159572A (en) * | 2011-09-21 | 2014-11-19 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | Nano delivery systems |
| CN104812397A (en) * | 2012-09-27 | 2015-07-29 | 阿勒根公司 | Biodegradable drug delivery systems for the sustained release of proteins |
| CN106687143A (en) * | 2014-08-01 | 2017-05-17 | 勃林格殷格翰动物保健有限公司 | Nanoparticles, methods of preparation, and uses thereof |
| CN107106509A (en) * | 2014-12-18 | 2017-08-29 | 帝斯曼知识产权资产管理有限公司 | Drug delivery system for delivering acid labile drug |
| CN104814934A (en) * | 2015-04-28 | 2015-08-05 | 吉林大学 | Herceptin modified paclitaxel-carried targeting nanoparticle transfer system |
Non-Patent Citations (1)
| Title |
|---|
| FELIPE L ET AL.: "Simultaneous Therapy with Intravitreal Dexamethasone Implant and Bevacizumab for the Treatment of Macular Edema", 《MED HYPOTHESIS DISCOV INNOV OPHTHALMOL》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114869862A (en) * | 2022-04-24 | 2022-08-09 | 温州医科大学附属眼视光医院 | Glaucoma surgery slow-release anti-scar membrane with drainage function and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Anti-angiogenic activity of bevacizumab-bearing dexamethasone-loaded PLGA nanoparticles for potential intravitreal applications | |
| CN110664757B (en) | Nanocrystalline eye drop, preparation method and application thereof | |
| US20100111984A1 (en) | Nanospheres encapsulating bioactive material and method for formulation of nanospheres | |
| Cheng et al. | Triamcinolone acetonide-chitosan coated liposomes efficiently treated retinal edema as eye drops | |
| JP2012504150A5 (en) | ||
| Wu et al. | Cell penetrating peptide TAT-functionalized liposomes for efficient ophthalmic delivery of flurbiprofen: Penetration and its underlying mechanism, retention, anti-inflammation and biocompatibility | |
| Radwan et al. | Chitosan-coated bovine serum albumin nanoparticles for topical tetrandrine delivery in glaucoma: in vitro and in vivo assessment | |
| Teng et al. | Targeted delivery of baicalein-p53 complex to smooth muscle cells reverses pulmonary hypertension | |
| CN106456707A (en) | Dry-powder peptide medicament | |
| CN107496901B (en) | Cell autophagy inhibitor and preparation method and application thereof | |
| CN109481403B (en) | Chitosan-modified triamcinolone acetonide acetate liposome and preparation method thereof | |
| Badr et al. | The topical ocular delivery of rapamycin to posterior eye tissues and the suppression of retinal inflammatory disease | |
| Li et al. | Micelles based on polyvinylpyrrolidone VA64: A potential nanoplatform for the ocular delivery of apocynin | |
| Li et al. | A novel, liposome-loaded, injectable hydrogel for enhanced treatment of choroidal neovascularization by sub-tenon's injection | |
| CN110051650A (en) | The nanoparticle pharmaceutical that bevacizumab and dexamethasone for intravitreal injection carry altogether | |
| Sun et al. | Combined anti-angiogenic and anti-inflammatory nanoformulation for effective treatment of ocular vascular diseases | |
| WO2011097577A2 (en) | Compositions and methods for treating or preventing retinal degeneration | |
| EP4141018A1 (en) | Peptide fg and its use in preparation of drugs for treating and preventing ocular fundus vascular diseases | |
| CN113813375B (en) | Composition of novel anti-novel coronavirus complex and application of novel anti-novel coronavirus complex in medicines for preventing and treating coronavirus infection diseases | |
| CN114099664B (en) | Treg cell exosome-based targeted synergistic drug system and preparation method thereof | |
| CN108697808A (en) | The drug delivery system based on protein nano structure for therapeutic agent to be delivered to anterior ocular segment | |
| CN113577083A (en) | Application of small molecule compound combination in preparation of medicine for preventing and treating retina injury diseases | |
| CN107569451B (en) | A kind of synthesis and its application of the degradable nano magnesia metal micelle complex of gene target | |
| CN110585168A (en) | Application of utilizing cell surface vesicle as drug carrier | |
| CN109646684B (en) | Cyclodextrin containing cyclosporin and its use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190726 |